Prospective, multicentric, multispecialty, international, open-label, single arm study using per-protocol intravascular ultrasound \[IVUS, 20MHz electronic phase-array transducer\] to document the procedure result of an effective plaque exclusion from the vessel lumen.
Investigator initiated, academic, single arm, open-label, non-randomized, prospective, multicenter, multispecialty trial of CGuard™ use in all-comer population of consecutive patients with carotid stenosis related cerebral symptoms (TIA, stroke, retinal TIA, retinal stroke) or signs of ipsilateral brain injury on MRI or CT imaging. The main objective of this observational study is to evaluate an incidence of residual plaque prolapse after carotid stenting using the study device. Study Rationale In conventional carotid stents, plaque prolapse (PP) on intravascular imaging had been determined to be strongly associated with new post-procedural diffusion-weighted magnetic resonance lesions on cerebral imaging and with increased ischaemic stroke incidence. A significant increase in PP susceptibility was observed with unstable carotid plaque, pointing to the limitations of conventional CAS in unstable carotid plaques, such as symptomatic and increased-spontaneous-symptoms-risk lesions. This is reflected in current guidelines that provide a higher recommendation class to surgical management (CEA) rather than CAS for symptomatic lesions. Circumstantial evidence indicates that the novel carotid stent covered with MicroNET (CGuard EPS) may be an optimal device for effective carotid plaque sequestration (that may be particularly relevant in high-risk plaques) - but no systematic study has been performed thus far. Because of the increasing evidence that not only clinical symptoms (that may be related to for instance the affection of dominant vs. non-dominant haemisphere) but also signs of ipisilateral cerebral infarct/s are a hallmark of high-risk plaque and are associated with adverse prognosis, and because that neurology increasingly uses the term "symptomatic" to refer to carotid stenosis associated with clinically silent ipisilateral cerebral infarct/s, the present study will enroll both patients with clinical symptoms of cerebral ischaemia in relation to carotid stenosis and those with (clinically silent) signs of ipsilateral injury such as ischemic focus/foci on CT or MRI/DW-MRI). As previously demonstrated, clinically significant/relevant PP is that depicted by IVUS (with angiography, on the one hand, being not sensitive enough and OCT, on the other, being possibly too sensitive).
Study Type
OBSERVATIONAL
Enrollment
200
IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
Department of Cardiac and Vascular Diseases, The John Paul II Hospital
Krakow, Maloplska, Poland
RECRUITINGFreedom from plaque prolapse
Freedom from plaque prolapse defined as observation of plaque inside the stent lumen after completion of the CAS procedure by IVUS assessment (Kotsugi 2017).
Time frame: During index procedure
Procedural success
stent delivery and implantation in absence of an intra-procedural clinical major adverse event, with no more than 30% residual diameter stenosis by on-site QCA, and successful withdrawal of the stent delivery and neuroprotection system
Time frame: During index procedure
IVUS interrogation success
IVUS interrogation with an effective IVUS probe removal in absence of any clinical complications
Time frame: During index procedure
Endovascular lumen reconstruction
Freedom from plaque prolapse plus minimal in-stent area \>50% ICA reference area
Time frame: During index procedure
Periprocedural MACCE
Death, stroke, myocardial infarction until discharge or up to 24 hours
Time frame: Until discharge or up to 24 hours
30 days MACCE
Death, stroke, myocardial infarction until 30 days
Time frame: 30 days
Any periprocedural complications
Any complications occurring until discharge or 24 hours whichever comes first
Time frame: Until discharge or up to 24 hours
Ipsilateral stroke between 31 days and 12 months after the procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ipsilateral stroke between 31 days and 12 months after the procedure
Time frame: Between 31 days and 12 months after the procedure
Duplex UltraSound (DUS) at 30 days
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) recorded by Duplex Doppler at 30±5 days after the procedure
Time frame: 30 days
Duplex UltraSound (DUS) at 12 months
Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) recorded by Duplex Doppler at 12 months after the procedure
Time frame: 12 months